دورية أكاديمية

Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study

التفاصيل البيبلوغرافية
العنوان: Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study
المؤلفون: Max Beugeling, Katie Amssoms, Freek Cox, Ben De Clerck, Ellen Van Gulck, Jeroen A. Verwoerd, Guenter Kraus, Dirk Roymans, Lieven Baert, Henderik W. Frijlink, Wouter L. J. Hinrichs
المصدر: Pharmaceutics, Vol 11, Iss 10, p 510 (2019)
بيانات النشر: MDPI AG, 2019.
سنة النشر: 2019
المجموعة: LCC:Pharmacy and materia medica
مصطلحات موضوعية: biphasic pulsatile release, controlled release, freeze-dried powder, fusion protein, poly(dl-lactic-co-glycolic acid), pre-fusion, respiratory syncytial virus, single-injection vaccine, Pharmacy and materia medica, RS1-441
الوصف: Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-co-glycolic acid) (PLGA) shell. We intended to develop a stable freeze-dried pre-F-containing powder. Furthermore, we investigated whether incorporation of this powder into the core-shell implant was feasible and whether this system would induce a delayed RSV virus-neutralizing antibody (VNA) response in mice. The developed pre-F-containing powder, consisting of pre-F in a matrix of inulin, HEPES, sodium chloride, and Tween 80, was stable during freeze-drying and storage for at least 28 days at 60 °C. Incorporation of this powder into the core-shell implant was feasible and the core-shell production process did not affect the stability of pre-F. An in vitro release study showed that pre-F was incompletely released from the core-shell implant after a lag time of 4 weeks. The incomplete release may be the result of pre-F instability within the core-shell implant during the lag time and requires further research. Mice subcutaneously immunized with a pre-F-containing core-shell implant showed a delayed RSV VNA response that corresponded with pre-F release from the core-shell implant after a lag time of approximately 4 weeks. Moreover, pre-F-containing core-shell implants were able to boost RSV VNA titers of primed mice after a lag time of 4 weeks. These findings could contribute to the development of a single-injection pre-F-based vaccine containing a primer and a booster.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1999-4923
Relation: https://www.mdpi.com/1999-4923/11/10/510; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics11100510
URL الوصول: https://doaj.org/article/1fab9f6aa5144ad296de6c6ca8e08c85
رقم الأكسشن: edsdoj.1fab9f6aa5144ad296de6c6ca8e08c85
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:19994923
DOI:10.3390/pharmaceutics11100510